Navigation Links
Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
Date:2/20/2008

Epilepsy Sales Increase Significantly

HOUSTON, Feb. 20 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced results for the fiscal year 2008 third quarter ended January 25, 2008.

Financial highlights

Net sales

Net sales for the third quarter of fiscal 2008 were $29.3 million, compared to $28.9 million in the second quarter of fiscal 2008 and $31.7 million in the third quarter of fiscal 2007. Net sales for the nine months ended January 25, 2008 were $87.3 million, compared to $99.5 million in the comparable period of the prior year; net sales in fiscal 2008 attributable to the epilepsy indication of $82.6 million have increased by 9.4% over fiscal 2007.

U.S. net sales for the third quarter of fiscal 2008 declined to $22.2 million, compared with $26.6 million in the comparable period of fiscal 2007. Overall, U.S. net sales declined due to the continued reduction in the number of VNS Therapy Systems attributable to treatment-resistant depression ("TRD"), following both the preliminary and final non-coverage determinations by the Centers for Medicare and Medicaid Services in February 2007 and May 2007, respectively; however, net sales attributable to the epilepsy indication increased by approximately 13% over the comparable prior year quarter.

International net sales increased by 36% to a record $6.9 million, up from the $5.1 million reported in the third quarter of fiscal 2007, due primarily to unit growth of 20%, the impact of foreign currency movements and improved pricing.

Net sales include $167,000 relating to the license fee of $9.5 million received during the third quarter. It is anticipated that this license fee will be recognized at a quarterly rate of $373,000 through the end of fiscal 2014. The unamortized amount is reflected as deferred revenue in long-term liabilities.

Gross margin

The gross margin for the third quarter of fiscal 2008 represente
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Cyberonics Licenses Obesity-Related Patents
2. Cyberonics Announces Conference Call to Discuss FY08 Q3 Financial Results
3. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
4. Haemacure Reports Third Quarter 2007 Results
5. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
6. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
7. MDS Reports Third Quarter 2007 Results
8. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
9. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
10. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
11. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... by a researcher from the Cancer Science Institute of ... has identified the cancer specific stem cell which causes ... developing new drugs for the treatment of this disease ... led by Dr Chan Shing Leng, Research Assistant Professor ... a cancer-specific variant of a cell surface protein, CD44v8-10, ...
(Date:4/23/2014)... known as Ritalin, may prevent the depletion of self-control, ... a journal of the Association for Psychological Science. , ... or trying to focus attention on a boring textbook ... potential explanation for this difficulty: Exerting self-control for a ... self-control effectively on subsequent tasks. , "It is as ...
(Date:4/22/2014)... leaders visited the New Jersey Institute of Technology ... Bloom for the launch of the New Jersey ... a new model for business innovation through the ... and investment. U.S. Senator Cory Booker, Panasonic Corp. ... New Jersey Lieutenant Governor Kim Guadagno, New Jersey ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern ... suffering from depression . , A team ... mechanism by which ghrelin (a hormone with natural anti-depressant ... a potentially powerful new treatment for depression in the ... , The study, published online in April,s issue ...
(Date:4/22/2014)... 2014) The International Communication Association will hold ... Washington. The theme of the 2014 conference will ... networked and digital society. , Featuring over 2,300 ... 2,200 Communication scholars representing over 40 countries, the ... conference in the world. This year,s conference features ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... 2010 (Portland, Ore.) A new study finds that ... up to a year and the program can also save ... most common eating disorder in the country, affecting more than ... few treatment options are available. But a first-of-a-kind study ...
... upon estrogens to survive and proliferate in about 70% ... treatment to fight this variety of tumours relies on ... of therapy develops in more than 30% of the ... resistance to tamoxifen is thus essential to develop new ...
... ... of Consumers Consider Apples a Value-Based Anytime Food for Both Adults and Children; ,Shoppers ... ... than three-out-of-four Americans, apples and apple beverages fill the dual purpose of being a ...
... gastric cancer patients who have had part or all ... post-operative weight loss and improve appetite, according to a ... of the American Gastroenterological Association (AGA) Institute. "It ... the side effects of gastrectomy. Our study provides convincing ...
... ... , ... 2010 -- Pat Heyward Canes, a new provider of fashion forward walking canes , ... women ranging from classic to whimsical. Made from performance materials, the canes can withstand ...
... ... key management to PCI compliance efforts , ... Salt Lake City, UT (Vocus) March 31, 2010 -- Venafi, ... the security risks they face when encryption keys are not properly monitored and managed., ...
Cached Medicine News:Health News:Short-term program for binge eaters has long-term benefits 2Health News:Short-term program for binge eaters has long-term benefits 3Health News:How breast cancer cells evade therapeutic attacks 2Health News:Apples Are the New Superfruit 2Health News:Apples Are the New Superfruit 3Health News:Apples Are the New Superfruit 4Health News:Promising hormone may help reduce malnutrition in gastric cancer patients 2Health News:Pat Heyward Canes Unveils New Stylish Walking Cane Collection Just in Time for Mother's Day 2Health News:PCI Compliance and Data Security Requires Private Key Management – New Industry White Paper Explains 2
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: